May 27, 2017 4:11 PM ET

Pharmaceuticals

Company Overview of Wanbang Biopharmaceuticals Co., Ltd.

Company Overview

Wanbang Biopharmaceuticals Co., Ltd. focuses on developing, manufacturing, and selling pharmaceuticals for patients of diabetes and related cardiovascular diseases. Its products include animal insulin, Glimepiride tablets, Meglumine Adenosine Cyclophosphate, EPO, Bangtan(Telmisatan), and Heparin sodium. The company’s products also comprise aloe compound capsules for clearing liver-heat, relaxing bowels, and calming heart for tranquillization; and products in the fields of chemicals, pharmaceuticals, and biotech, such as Human Interferon ?, Human Erythropoietin, Streptokinase, and Pemetrexed disodium. It sells products through a network of distributors and sales representatives in China and i...

No.6 Yangshan Road

Jinshanqiao Economic Zone

Xuzhou,  221004

China

Founded in 1981

Phone:

86 516 8381 7058

Fax:

86 516 8381 7058

Key Executives for Wanbang Biopharmaceuticals Co., Ltd.

President
Age: 47
Senior Vice President
Vice President and Secretary
Age: 45
Vice President
Vice President
Compensation as of Fiscal Year 2016.

Wanbang Biopharmaceuticals Co., Ltd. Key Developments

Rockwell Medical, Inc. Enters into Licensing and Manufacturing Supply Agreements with Wanbang Biopharmaceutical Co., Ltd

On February 16, 2016, Rockwell Medical, Inc. announced that it entered into exclusive licensing and manufacturing supply agreements with Wanbang Biopharmaceutical Co. Ltd. for the rights to commercialize the company's Triferic and Calcitriol for end stage-renal disease patients, that also includes new therapeutic indications for Triferic, in the People's Republic of China. Triferic is the company's proprietary iron replacement and hemoglobin maintenance drug for treating anemia. Calcitriol is the company's generic (active vitamin D) injection for treatment of secondary hyperparathyroidism in dialysis patients. Under the terms of the agreement, the company will become the exclusive distributor for Triferic and Calcitriol in China for an initial commercial term of ten years, with an extended term of 10 or more years based on achievement of annual minimum purchase requirements. In consideration for the exclusive rights, the company will receive from the company an upfront fee plus regulatory and revenue milestone payments totaling $39 million in aggregate. Notably, the company will receive ongoing earnings from product sales of Triferic and Calcitriol, and other additional Triferic therapeutic indications. The company retains manufacturing responsibility of all products. The company is required to achieve annual minimum purchase requirements to retain exclusive commercialization rights. In addition to the hemodialysis indication, the company has the exclusive right to develop and commercialize Triferic for new therapeutic indications for the Chinese market. The company is responsible for all clinical, regulatory and marketing expenses for Triferic and Calcitriol in China as well as development and regulatory costs for new Triferic indications.

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
December 22, 2016
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Wanbang Biopharmaceuticals Co., Ltd., please visit www.chinawanbang.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.